SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), a commercial-stage biopharmaceutical company, has announced the commencement of a Phase 1 clinical trial for F230, targeting pulmonary arterial hypertension (PAH). The first volunteer has been successfully dosed in this trial, which aims to evaluate the safety, tolerability, and pharmacokinetics of F230 in healthy volunteers. This trial signifies Gyre's expansion into the PAH field, a condition with limited treatment options. F230, a novel endothelin A receptor antagonist, is designed to mitigate pulmonary vascular remodeling and reduce pulmonary pressure. Results from this Phase 1 trial have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.